Connective tissue growth factor inhibition attenuates left ventricular remodeling and dysfunction in pressure overload-induced heart failure

Hypertension

Volumn 63, Issue 6, 2014, Pages 1235-1240

  Szabó, Zoltán ^a   Magga, Johanna ^a   Alakoski, Tarja ^a   Ulvila, Johanna ^a   Piuhola, Jarkko ^a   Vainio, Laura ^a   Kivirikko, Kari I ^a   Vuolteenaho, Olli ^a   Ruskoaho, Heikki ^a,c   Lipson, Kenneth E ^d   Signore, Pierre ^d   Kerkelä, Risto ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d FIBROGEN INC   (United States)

Author keywords

Connective tissue growth factor; Fibrosis; Hypertrophy, left ventricular; Ventricular dysfunction, left; Ventricular remodeling

Indexed keywords

ANGIOTENSIN II; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY; FG 3149; GELATINASE A; IMMUNOGLOBULIN G; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE COURSE; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HEART; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; THORACIC AORTIC CONSTRICTION;

CONNECTIVE TISSUE GROWTH FACTOR; FIBROSIS; HYPERTROPHY, LEFT VENTRICULAR; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

ANGIOTENSIN II; ANIMALS; ANTIBODIES, MONOCLONAL; AORTA, THORACIC; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; CONSTRICTION, PATHOLOGIC; FIBROBLASTS; GENE EXPRESSION; HEART; HEART FAILURE; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRESSURE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING; WEIGHT-BEARING;

EID: 84902288558     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03279     Document Type: Article

References (26)

1. Spinale FG, Janicki JS, Zile MR. Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013;112:195-208.
2. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 2010;106:1675-1680.
3. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol. 2009;41:771-783.
4. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev. 2012;92:635-688.
5. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol. 1999;181:153-159.
6. Kemp TJ, Aggeli IK, Sugden PH, Clerk A. Phenylephrine and endothelin- 1 upregulate connective tissue growth factor in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 2004;37:603-606.
7. Koitabashi N, Arai M, Niwano K, et al. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail. 2008;10:373-379.
8. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y, Maeno T, Nishida T, Kubota S, Takigawa M, Kurabayashi M. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension. 2007;49:1120-1127.
9. Ahmed MS, Øie E, Vinge LE, Yndestad A, Øystein Andersen G, Andersson Y, Attramadal T, Attramadal H. Connective tissue growth factor-a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol. 2004;36:393-404.
10. Yoon PO, Lee MA, Cha H, Jeong MH, Kim J, Jang SP, Choi BY, Jeong D, Yang DK, Hajjar RJ, Park WJ. The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. J Mol Cell Cardiol. 2010;49:294-303.
11. Ahmed MS, Gravning J, Martinov VN, von Lueder TG, Edvardsen T, Czibik G, Moe IT, Vinge LE, Øie E, Valen G, Attramadal H. Mechanisms of novel cardioprotective functions of CCN2/CTGF in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2011;300:H1291-H1302.
12. Panek AN, Posch MG, Alenina N, Ghadge SK, Erdmann B, Popova E, Perrot A, Geier C, Dietz R, Morano RD, Morano I, Bader M, Ozcelik C. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One. 2009;4:e6743.
13. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol. 2012;227:493-507.
14. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 1995;25:1252-1259.
15. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res. 1998;40:352-363.
16. Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension. 2009;54:877-884.
17. Booth AJ, Csencsits-Smith K, Wood SC, Lu G, Lipson KE, Bishop DK. Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant. 2010;10:220-230.
18. Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, Kassiri Z, Fernandez-Patron C. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension. 2011;57:123-130.
19. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 2001;103:2303-2309.
20. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, Kinugawa S, Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension. 2006;47:711-717.
21. Fan WH, Karnovsky MJ. Increased MMP-2 expression in connective tissue growth factor over-expression vascular smooth muscle cells. J Biol Chem. 2002;277:9800-9805.
22. Droppelmann CA, Gutiérrez J, Vial C, Brandan E. Matrix metalloproteinase-2-deficient fibroblasts exhibit an alteration in the fibrotic response to connective tissue growth factor/CCN2 because of an increase in the levels of endogenous fibronectin. J Biol Chem. 2009;284:13551-13561.
23. Xiang G, Schuster MD, Seki T, Witkowski P, Eshghi S, Itescu S. Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction. J Am Coll Cardiol. 2005;46:536-541.
24. Pathak M, Sarkar S, Vellaichamy E, Sen S. Role of myocytes in myocardial collagen production. Hypertension. 2001;37:833-840.
25. Shibasaki Y, Nishiue T, Masaki H, Tamura K, Matsumoto N, Mori Y, Nishikawa M, Matsubara H, Iwasaka T. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens Res. 2005;28:787-795.
26. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084-1091